June 28, 2017
RegMed Investors’ (RMi) pre-open indications, time to walk
June 27, 2017
Histogenics (HSGX) P3 Clinical Trial of Neocart® enrollment completed to Treat Knee Cartilage Damage - BUY
June 27, 2017
RegMed Investors’ (RMi) pre-open indications, the slippage begins
June 26, 2017
RegMed Investors’ (RMi) closing bell, what news as the sector stays up …
June 22, 2017
RegMed Investors’ (RMi) closing bell, still in a sprint mode with strong gains
June 8, 2017
RegMed Investors’ (RMi) closing bell, political words were a basis for today’s session
May 30, 2017
RegMed Investors’ (RMi) pre-open indications, we’re back …
May 23, 2017
RegMed Investors’ (RMi) pre-open indications, Insight is interpreting perception
May 19, 2017
RegMed Investors’ (RMi) closing bell, kissing- up to the fundamentals we stand with
May 16, 2017
RegMed Investors’ (RMi) pre-open indications, discounted stocks in a cheap market
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.